241 related articles for article (PubMed ID: 15584861)
21. Targeting mutants of PTEN reveal distinct subsets of tumour suppressor functions.
Leslie NR; Bennett D; Gray A; Pass I; Hoang-Xuan K; Downes CP
Biochem J; 2001 Jul; 357(Pt 2):427-35. PubMed ID: 11439092
[TBL] [Abstract][Full Text] [Related]
22. INPP4B Is a PtdIns(3,4,5)P3 Phosphatase That Can Act as a Tumor Suppressor.
Kofuji S; Kimura H; Nakanishi H; Nanjo H; Takasuga S; Liu H; Eguchi S; Nakamura R; Itoh R; Ueno N; Asanuma K; Huang M; Koizumi A; Habuchi T; Yamazaki M; Suzuki A; Sasaki J; Sasaki T
Cancer Discov; 2015 Jul; 5(7):730-9. PubMed ID: 25883023
[TBL] [Abstract][Full Text] [Related]
23. PTEN inhibits insulin-stimulated MEK/MAPK activation and cell growth by blocking IRS-1 phosphorylation and IRS-1/Grb-2/Sos complex formation in a breast cancer model.
Weng LP; Smith WM; Brown JL; Eng C
Hum Mol Genet; 2001 Mar; 10(6):605-16. PubMed ID: 11230180
[TBL] [Abstract][Full Text] [Related]
24. Regulation of PI3K effector signalling in cancer by the phosphoinositide phosphatases.
Rodgers SJ; Ferguson DT; Mitchell CA; Ooms LM
Biosci Rep; 2017 Feb; 37(1):. PubMed ID: 28082369
[TBL] [Abstract][Full Text] [Related]
25. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway.
Ramaswamy S; Nakamura N; Vazquez F; Batt DB; Perera S; Roberts TM; Sellers WR
Proc Natl Acad Sci U S A; 1999 Mar; 96(5):2110-5. PubMed ID: 10051603
[TBL] [Abstract][Full Text] [Related]
26. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC.
Haas-Kogan D; Shalev N; Wong M; Mills G; Yount G; Stokoe D
Curr Biol; 1998 Oct; 8(21):1195-8. PubMed ID: 9799739
[TBL] [Abstract][Full Text] [Related]
27. TPIP: a novel phosphoinositide 3-phosphatase.
Walker SM; Downes CP; Leslie NR
Biochem J; 2001 Dec; 360(Pt 2):277-83. PubMed ID: 11716755
[TBL] [Abstract][Full Text] [Related]
28. Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signaling.
Zhang D; Brodt P
Oncogene; 2003 Feb; 22(7):974-82. PubMed ID: 12592384
[TBL] [Abstract][Full Text] [Related]
29. Living with lethal PIP3 levels: viability of flies lacking PTEN restored by a PH domain mutation in Akt/PKB.
Stocker H; Andjelkovic M; Oldham S; Laffargue M; Wymann MP; Hemmings BA; Hafen E
Science; 2002 Mar; 295(5562):2088-91. PubMed ID: 11872800
[TBL] [Abstract][Full Text] [Related]
30. Role of PTEN and Akt in the regulation of growth and apoptosis in human osteoblastic cells.
Nielsen-Preiss SM; Silva SR; Gillette JM
J Cell Biochem; 2003 Dec; 90(5):964-75. PubMed ID: 14624456
[TBL] [Abstract][Full Text] [Related]
31. Regulation of phosphoinositide metabolism, Akt phosphorylation, and glucose transport by PTEN (phosphatase and tensin homolog deleted on chromosome 10) in 3T3-L1 adipocytes.
Ono H; Katagiri H; Funaki M; Anai M; Inukai K; Fukushima Y; Sakoda H; Ogihara T; Onishi Y; Fujishiro M; Kikuchi M; Oka Y; Asano T
Mol Endocrinol; 2001 Aug; 15(8):1411-22. PubMed ID: 11463863
[TBL] [Abstract][Full Text] [Related]
32. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease.
Oudit GY; Sun H; Kerfant BG; Crackower MA; Penninger JM; Backx PH
J Mol Cell Cardiol; 2004 Aug; 37(2):449-71. PubMed ID: 15276015
[TBL] [Abstract][Full Text] [Related]
33. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors.
Bianco R; Shin I; Ritter CA; Yakes FM; Basso A; Rosen N; Tsurutani J; Dennis PA; Mills GB; Arteaga CL
Oncogene; 2003 May; 22(18):2812-22. PubMed ID: 12743604
[TBL] [Abstract][Full Text] [Related]
34. In vivo analysis of 3-phosphoinositide dynamics during Dictyostelium phagocytosis and chemotaxis.
Dormann D; Weijer G; Dowler S; Weijer CJ
J Cell Sci; 2004 Dec; 117(Pt 26):6497-509. PubMed ID: 15572406
[TBL] [Abstract][Full Text] [Related]
35. The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif.
Walker SM; Leslie NR; Perera NM; Batty IH; Downes CP
Biochem J; 2004 Apr; 379(Pt 2):301-7. PubMed ID: 14711368
[TBL] [Abstract][Full Text] [Related]
36. PTEN gene and integrin signaling in cancer.
Tamura M; Gu J; Tran H; Yamada KM
J Natl Cancer Inst; 1999 Nov; 91(21):1820-8. PubMed ID: 10547389
[TBL] [Abstract][Full Text] [Related]
37. PTEN signaling pathways in melanoma.
Wu H; Goel V; Haluska FG
Oncogene; 2003 May; 22(20):3113-22. PubMed ID: 12789288
[TBL] [Abstract][Full Text] [Related]
38. Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells.
Lin HK; Hu YC; Lee DK; Chang C
Mol Endocrinol; 2004 Oct; 18(10):2409-23. PubMed ID: 15205473
[TBL] [Abstract][Full Text] [Related]
39. Nuclear PTEN-mediated growth suppression is independent of Akt down-regulation.
Liu JL; Sheng X; Hortobagyi ZK; Mao Z; Gallick GE; Yung WK
Mol Cell Biol; 2005 Jul; 25(14):6211-24. PubMed ID: 15988030
[TBL] [Abstract][Full Text] [Related]
40. PTEN: The down side of PI 3-kinase signalling.
Leslie NR; Downes CP
Cell Signal; 2002 Apr; 14(4):285-95. PubMed ID: 11858936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
